🔗 Share this article

A shadow market for unapproved weight-loss medications is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.

Investigational Drug Acquiring Traction Via Social Media

Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning properties. Followers are encouraged to message these accounts directly for source information, while also receiving discount codes.

Thriving Commerce on Messaging Platforms

Separately, a robust trade exists on messaging services, where communities with thousands of participants share comparison images, administration instructions and claims of rapid British shipping. Sellers market the substance there before directing customers to WhatsApp for purchases.

Learning About The Experimental Drug

This medication is an investigational injection created by US drugmaker Eli Lilly. The drug targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could assist individuals lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the next Ozempic.

Medical Professionals Express Concerns

However, doctors and chemists have cautions that the sale of what is still an unapproved medication in the United Kingdom is worrisome and could result in users injecting products of uncertain source.

Several professionals said the popularity for the experimental drug could be connected to the rising cost of approved slimming products such as Mounjaro.

Legal Position and Implementation

Marketing the unapproved drug on TikTok or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some content creators try to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and distribution can still violate medicines, marketing, and customer regulations, potentially leading to fines, legal action or prison.

Platform Reaction and Material Elimination

According to the social media company, the platform has removed problematic material and banned related keywords and search suggestions. The company said it was dedicated to keeping the service secure and investing in strengthening enforcement strategies.

Digital Trading Activities

Research also discovered groups with up to 9,000 members selling the experimental drug using Telegram's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” instantly displays groups with thousands of users, populated with images of weight loss, glowing testimonials and step-by-step guides for preparing or injecting at residence.

Within moments of joining one community, a seller shared contact information, where the majority of transactions occur. The seller sent an instruction manual and promised delivery within two days. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one asked about weight, health issues or past usage.

Product Details and Costs

Inside these groups, messages show black plastic parcels with Royal Mail labels, claiming to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between powder vials, prepared at residence with purified liquid, or pre-filled injectors typically sold at 160 pounds for 20 milligrams. When questioned how long a pen should be used, sellers give conflicting answers ranging from a few weeks to “depends on your body”.

Service Oversight and Safety Actions

A representative for Telegram said it actively monitored dangerous content on its service including content that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“Individuals are administering materials they can’t verify. Even if the research behind this drug is sound, these online versions may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to current cost increases for authorized slimming drugs such as Mounjaro. “With costs increasing, patients are turning to online platforms. But counterfeit injections are extremely risky. You cannot know what’s inside or whether the environment they were made in was sterile,” she explained.

Her team has already seen individuals harmed by personal administration from unverified suppliers. “We recognize the frustration, but buying from Telegram or communication platforms is gambling with your well-being,” said the doctor. “These materials could be impure or incorrectly dosed.”

Producer Statement

A representative from Eli Lilly stated the substance was in phase 3 clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this point no one can sell [it] for human use,” they said, noting that any item “misleadingly claiming itself as a company experimental substance not yet approved … may subject users to potentially serious medical dangers”.